Drugs / sodium salicylate

Trials 1

19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00004245 Aug 1999 → Sep 2004 leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm Memorial Sloan Kettering Cancer Center Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as sodium salicylate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004245 ↗
Known as Alysine ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Enterosalicyl ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Kerasalicyl ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Natrii salicylas ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Natrum salicylicum ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as NSC-202167 ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Salicylate sodium ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Salicylic acid sodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Known as Sod sal ChEMBL registry synonym — accepted as the source's own label CHEMBL447868 ↗
Action Inhibit “which inhibits NF-κB in in vitro models.” PMID 22154022 ↗ Dec 2011
Modality Small molecule — CHEMBL447868 ↗
Route Oral “Patients receive oral sodium salicylate twice a day.” NCT00004245 ↗